Research
Hormonal
Glucagon-Thyroid Hormone (T3) conjugates reduce liver fat and improve dyslipidemia in obesity models by targeting the liver specifically, avoiding the cardiac and skeletal side effects of systemic T3 therapy.
Research is exploring new ways to deliver thyroid hormones to the liver to treat fatty liver disease without affecting the heart or bones. One promising approach involves linking T3 to glucagon to target the liver. This is still experimental and not available as a standard treatment.
ModerateSupportsMEDIUM confidence
Glucagon/T3 elicited the transcriptional activity of a TRE reporter in cells expressing the glucagon receptor... preferentially accumulated by the liver... Glucagon/T3 treatment improved dyslipidemia, atherosclerosis, body weight, and steatosis in several dietary models of obesity... The cardiac side effects of T3 on the heart... were not observed with treatment with glucagon/T3.
Why this rating
Based on animal models and in vitro studies; clinical efficacy in humans is not yet established.
Source
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
Rohit A. Sinha et al. · Thyroid · 2019
DOI 10.1089/thy.2018.0664
narrative_reviewCited 262×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Thyroid hormone receptor beta (THRβ) agonists and specific thyroid hormone metabolites (T2, T1AM) reduce hepatic lipid content and serum cholesterol in NAFLD and hypercholesterolemia models by stimulating fatty acid oxidation and cholesterol clearance without the cardiac side effects of natural thyroid hormones.Moderate
- Thyroid-stimulating hormone (TSH) directly promotes hepatic lipogenesis and cholesterol biosynthesis, worsening NAFLD and hypercholesterolemia, independent of its role in stimulating thyroid hormone production.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →